Cellectis Announces Participation in Upcoming Investor Conferences
Cellectis, a clinical-stage biotech company specializing in gene editing and CAR T-cell therapies, announced its participation in several upcoming healthcare investor conferences across the US and Europe. Management will engage with investors and present updates on the company's developments and strategic direction, continuing to promote its pionee…